JP2010524489A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010524489A5 JP2010524489A5 JP2010504835A JP2010504835A JP2010524489A5 JP 2010524489 A5 JP2010524489 A5 JP 2010524489A5 JP 2010504835 A JP2010504835 A JP 2010504835A JP 2010504835 A JP2010504835 A JP 2010504835A JP 2010524489 A5 JP2010524489 A5 JP 2010524489A5
- Authority
- JP
- Japan
- Prior art keywords
- binding domain
- amino acid
- acid sequence
- sequence shown
- domain consisting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 6
- 102100024654 Calcitonin gene-related peptide type 1 receptor Human genes 0.000 claims 5
- 101000760563 Homo sapiens Calcitonin gene-related peptide type 1 receptor Proteins 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 101000584593 Homo sapiens Receptor activity-modifying protein 3 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 102100030711 Receptor activity-modifying protein 3 Human genes 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- -1 carrier Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0708002.1A GB0708002D0 (en) | 2007-04-25 | 2007-04-25 | Antibodies |
| PCT/GB2008/001454 WO2008132453A1 (en) | 2007-04-25 | 2008-04-23 | Antibodies against ramp3 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014102881A Division JP6086495B2 (ja) | 2007-04-25 | 2014-05-16 | Ｒａｍｐ３に対する抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010524489A JP2010524489A (ja) | 2010-07-22 |
| JP2010524489A5 true JP2010524489A5 (OSRAM) | 2011-06-16 |
Family
ID=38170659
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010504835A Pending JP2010524489A (ja) | 2007-04-25 | 2008-04-23 | Ｒａｍｐ３に対する抗体 |
| JP2014102881A Expired - Fee Related JP6086495B2 (ja) | 2007-04-25 | 2014-05-16 | Ｒａｍｐ３に対する抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014102881A Expired - Fee Related JP6086495B2 (ja) | 2007-04-25 | 2014-05-16 | Ｒａｍｐ３に対する抗体 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8389237B2 (OSRAM) |
| EP (1) | EP2152753B1 (OSRAM) |
| JP (2) | JP2010524489A (OSRAM) |
| KR (1) | KR20100015915A (OSRAM) |
| CN (1) | CN101842390A (OSRAM) |
| AU (1) | AU2008244074B2 (OSRAM) |
| CA (1) | CA2685099A1 (OSRAM) |
| ES (1) | ES2393938T3 (OSRAM) |
| GB (1) | GB0708002D0 (OSRAM) |
| WO (1) | WO2008132453A1 (OSRAM) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030114410A1 (en) | 2000-08-08 | 2003-06-19 | Technion Research And Development Foundation Ltd. | Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis |
| GB0521139D0 (en) * | 2005-10-18 | 2005-11-23 | Univ Sheffield | Therapeutic agent |
| EP2006381B1 (en) | 2006-03-31 | 2016-02-03 | Chugai Seiyaku Kabushiki Kaisha | Method for controlling blood pharmacokinetics of antibodies |
| AU2007255753B2 (en) | 2006-06-08 | 2013-01-17 | Chugai Seiyaku Kabushiki Kaisha | Preventive or remedy for inflammatory disease |
| CA2693310C (en) | 2007-08-02 | 2018-11-27 | Arresto Biosciences, Inc. | Lox and loxl2 inhibitors, antibodies and uses thereof |
| CL2008002886A1 (es) | 2007-09-26 | 2009-12-04 | Chugai Pharmaceutical Co Ltd | Region constante de un anticuerpo humano; anticuerpo anti-receptor de interleucina-6 (il-6) y composicion farmaceutica que la comprende. |
| CA2700701C (en) | 2007-09-26 | 2020-12-29 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
| RU2596397C2 (ru) | 2007-12-05 | 2016-09-10 | Чугаи Сейяку Кабусики Кайся | Терапевтическое средство от зуда |
| WO2009072604A1 (ja) | 2007-12-05 | 2009-06-11 | Chugai Seiyaku Kabushiki Kaisha | 抗nr10抗体、およびその利用 |
| NZ717429A (en) | 2008-04-11 | 2018-07-27 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| CA2722466A1 (en) * | 2008-04-29 | 2009-11-05 | Tariq Ghayur | Dual variable domain immunoglobulins and uses thereof |
| SG191639A1 (en) | 2008-06-03 | 2013-07-31 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| EP2297208A4 (en) * | 2008-06-03 | 2012-07-11 | Abbott Lab | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES |
| KR20110031369A (ko) * | 2008-07-08 | 2011-03-25 | 아보트 러보러터리즈 | 프로스타글란딘 ｅ2 이원 가변 도메인 면역글로불린 및 이의 용도 |
| KR20160062207A (ko) * | 2008-12-05 | 2016-06-01 | 추가이 세이야쿠 가부시키가이샤 | 항ｎｒ１０ 항체 및 그의 이용 |
| JO3382B1 (ar) | 2008-12-23 | 2019-03-13 | Amgen Inc | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
| US9107935B2 (en) | 2009-01-06 | 2015-08-18 | Gilead Biologics, Inc. | Chemotherapeutic methods and compositions |
| WO2010107110A1 (ja) | 2009-03-19 | 2010-09-23 | 中外製薬株式会社 | 抗体定常領域改変体 |
| EP2826789A1 (en) | 2009-03-19 | 2015-01-21 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
| WO2010127294A2 (en) * | 2009-05-01 | 2010-11-04 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
| TW201109438A (en) * | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| WO2011022667A2 (en) | 2009-08-21 | 2011-02-24 | Arresto Biosciences, Inc | Catalytic domains from lysyl oxidase and loxl2 |
| TW201119676A (en) * | 2009-10-15 | 2011-06-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| UY32979A (es) * | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| EP2601218A4 (en) | 2010-08-03 | 2015-02-18 | Abbvie Inc | VARIABLE DOUBLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF |
| BR112013004581A2 (pt) | 2010-08-26 | 2017-06-27 | Abbvie Inc | imunoglobulinas de domínio variável dual e seus usos |
| CN108715614A (zh) | 2010-11-30 | 2018-10-30 | 中外制药株式会社 | 与多分子的抗原重复结合的抗原结合分子 |
| EP4530630A3 (en) * | 2011-10-26 | 2025-06-18 | Elanco Tiergesundheit AG | Monoclonal antibodies and methods of use |
| JP2015508994A (ja) | 2011-12-30 | 2015-03-26 | アッヴィ・インコーポレイテッド | Ｉｌ−１３および／またはｉｌ−１７に対する二重可変ドメイン免疫グロブリン |
| RU2636043C2 (ru) | 2012-11-01 | 2017-11-17 | Эббви Инк. | Анти-vegf/dll4-иммуноглобулины с двойными вариабельными доменами и их применения |
| CN105324396A (zh) | 2013-03-15 | 2016-02-10 | 艾伯维公司 | 针对IL-1β和/或IL-17的双重特异性结合蛋白 |
| US10379127B2 (en) | 2013-11-27 | 2019-08-13 | Welcome Receptor Antibodies Pty Ltd | Marker of cell death |
| JP6956631B2 (ja) | 2014-09-15 | 2021-11-02 | アムジェン インコーポレイテッド | 二重特異性抗ｃｇｒｐ受容体／ｐａｃ１受容体抗原結合タンパク質及びその使用 |
| US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
| FI3284480T3 (fi) | 2015-04-14 | 2025-09-11 | Chugai Pharmaceutical Co Ltd | IL-31-antagonistia vaikuttavana ainesosana sisältävä farmaseuttinen koostumus atooppisen ihottuman ehkäisemiseksi ja/tai hoitamiseksi |
| BR112017022101A2 (pt) | 2015-04-14 | 2018-07-31 | Chugai Seiyaku Kabushiki Kaisha | composição farmacêutica para prevenção e/ou tratamento de dermatite atópica contendo antagonista de il-31 como ingrediente ativo |
| JOP20200116A1 (ar) | 2015-04-24 | 2017-06-16 | Amgen Inc | طرق لعلاج أو الوقاية من الصداع النصفي |
| EP4060344A1 (en) | 2015-06-08 | 2022-09-21 | Arquer Diagnostics Limited | Methods and kits |
| GB201509907D0 (en) * | 2015-06-08 | 2015-07-22 | Urosens Ltd | Antibodies |
| US11519916B2 (en) | 2015-06-08 | 2022-12-06 | Arquer Diagnostics Limited | Methods for analysing a urine sample |
| TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白 |
| CA3021098A1 (en) | 2016-04-21 | 2017-10-26 | Abbvie Stemcentrx Llc | Novel anti-bmpr1b antibodies and methods of use |
| GB201707938D0 (en) | 2017-05-17 | 2017-06-28 | Univ Sheffield | Compounds |
| US11407838B2 (en) | 2018-04-02 | 2022-08-09 | Amgen Inc. | Erenumab compositions and uses thereof |
| WO2020076791A2 (en) * | 2018-10-08 | 2020-04-16 | The Uab Research Foundation | Neuroendocrine cancer targeted therapy |
| GB201818649D0 (en) | 2018-11-15 | 2019-01-02 | Univ Sheffield | Compounds |
| GB201818651D0 (en) | 2018-11-15 | 2019-01-02 | Univ Sheffield | Compounds |
| IL293099B2 (en) | 2019-11-20 | 2025-07-01 | Chugai Pharmaceutical Co Ltd | Antibody-containing preparation |
| CN112920267B (zh) * | 2021-03-09 | 2021-08-13 | 北京康乐卫士生物技术股份有限公司 | 一种抗人乳头瘤病毒31型的单克隆中和抗体及其应用 |
| WO2024102912A1 (en) * | 2022-11-10 | 2024-05-16 | The Children's Medical Center Corporation | Cgrp/ramp1 blockade to treat endometriosis-associated pain and reduce endometriosis lesions |
| GB202303531D0 (en) * | 2023-03-10 | 2023-04-26 | Fusion Antibodies Plc | Antibodies and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030055231A1 (en) * | 1998-10-28 | 2003-03-20 | Jian Ni | 12 human secreted proteins |
| AU2003298708A1 (en) * | 2002-11-27 | 2004-06-23 | Genpath Pharmaceuticals, Incorporated | GPC99 AND GPC99a: METHODS AND COMPOSITIONS FOR TREATING CANCER |
| GB0521139D0 (en) * | 2005-10-18 | 2005-11-23 | Univ Sheffield | Therapeutic agent |
-
2007
- 2007-04-25 GB GBGB0708002.1A patent/GB0708002D0/en not_active Ceased
-
2008
- 2008-04-23 KR KR1020097022348A patent/KR20100015915A/ko not_active Withdrawn
- 2008-04-23 US US12/597,269 patent/US8389237B2/en not_active Expired - Fee Related
- 2008-04-23 JP JP2010504835A patent/JP2010524489A/ja active Pending
- 2008-04-23 CN CN200880013626A patent/CN101842390A/zh active Pending
- 2008-04-23 CA CA002685099A patent/CA2685099A1/en not_active Abandoned
- 2008-04-23 WO PCT/GB2008/001454 patent/WO2008132453A1/en not_active Ceased
- 2008-04-23 EP EP08750480A patent/EP2152753B1/en not_active Not-in-force
- 2008-04-23 ES ES08750480T patent/ES2393938T3/es active Active
- 2008-04-23 AU AU2008244074A patent/AU2008244074B2/en not_active Ceased
-
2013
- 2013-02-07 US US13/762,266 patent/US20130189285A1/en not_active Abandoned
-
2014
- 2014-05-16 JP JP2014102881A patent/JP6086495B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010524489A5 (OSRAM) | ||
| JP2012121878A5 (OSRAM) | ||
| JP2012522010A5 (OSRAM) | ||
| JP2019522490A5 (OSRAM) | ||
| JP2010511388A5 (OSRAM) | ||
| JP2019510739A5 (OSRAM) | ||
| JP2006506333A5 (OSRAM) | ||
| JP2014509187A5 (OSRAM) | ||
| JP2013519364A5 (OSRAM) | ||
| CA2624935A1 (en) | Anti-myostatin antibodies | |
| JP2009511579A5 (OSRAM) | ||
| JP2009511480A5 (OSRAM) | ||
| EA200801520A1 (ru) | Химерные и гуманизированные антитела против человеческого интерлейкина-13 (il-13) | |
| JP2008542278A5 (OSRAM) | ||
| JP2015525230A5 (OSRAM) | ||
| JP2012525128A5 (OSRAM) | ||
| NO20081987L (no) | Humane, monoklonale antistoffer mot CD70 | |
| JP2015525791A5 (OSRAM) | ||
| JP2009515831A5 (OSRAM) | ||
| JP2008516970A5 (OSRAM) | ||
| JP2021501744A5 (OSRAM) | ||
| JP2010533498A5 (OSRAM) | ||
| FI3569620T3 (fi) | Ihmisen cgrp-reseptoria sitovat vasta-aineet | |
| JP2012010714A5 (OSRAM) | ||
| JP2010531140A5 (OSRAM) |